{"id":52707,"date":"2026-01-04T15:02:05","date_gmt":"2026-01-04T07:02:05","guid":{"rendered":"https:\/\/flcube.com\/?p=52707"},"modified":"2026-01-04T15:02:06","modified_gmt":"2026-01-04T07:02:06","slug":"insilico-medicine-and-hisun-pharma-nominate-pcc-in-8-months-via-ai-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52707","title":{"rendered":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) and <strong>Hisun Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600267:SHA\">SHA: 600267<\/a>) announced the nomination of a <strong>Preclinical Candidate (PCC)<\/strong> for their collaborative project just <strong>eight months<\/strong> after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s <strong>Pharma.AI<\/strong> platform in accelerating early\u2011stage drug discovery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-milestone\">Partnership Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Insilico Medicine (3696.HK), Hisun Pharmaceutical (600267.SH)<\/td><\/tr><tr><td><strong>Agreement<\/strong><\/td><td>Strategic partnership signed April\u202f2025<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Insilico\u2019s proprietary Pharma.AI platform<\/td><\/tr><tr><td><strong>Achievement<\/strong><\/td><td>PCC nomination<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>8 months from partnership initiation<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Co\u2011development of AI\u2011driven innovative drugs for selected therapeutic targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<p><strong>Accelerated R&amp;D Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Traditional drug discovery<\/strong>: 12\u201118 months to PCC nomination<\/li>\n\n\n\n<li><strong>AI\u2011driven approach<\/strong>: <strong>8 months<\/strong> demonstrates <strong>30\u201150% time savings<\/strong><\/li>\n\n\n\n<li><strong>Cost Efficiency<\/strong>: Estimated <strong>40% reduction<\/strong> in early\u2011stage R&amp;D expenses<\/li>\n<\/ul>\n\n\n\n<p><strong>Portfolio Impact<\/strong>: The PCC nomination marks the <strong>first tangible output<\/strong> from the partnership, validating Insilico\u2019s <strong>generative AI capabilities<\/strong> and Hisun\u2019s <strong>biopharmaceutical development expertise<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-pharma-ai-platform\">Technology Profile: Pharma.AI Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capabilities<\/strong>: <strong>Chemistry42<\/strong> for de novo molecule design, <strong>PandaOmics<\/strong> for target identification, <strong>InClinico<\/strong> for trial prediction<\/li>\n\n\n\n<li><strong>Efficiency<\/strong>: Completed <strong>target validation, hit identification, lead optimization, and preclinical studies<\/strong> in 8 months<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Integrates <strong>deep learning<\/strong> with <strong>biological data<\/strong> to predict efficacy and safety profiles early<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-market-context\">Deal Structure &amp; Market Context<\/h2>\n\n\n\n<p><strong>Financial Terms<\/strong>: Undisclosed; typical AI\u2011driven partnerships involve <strong>milestone\u2011based payments<\/strong> and <strong>royalty sharing<\/strong>.<\/p>\n\n\n\n<p><strong>Market Opportunity<\/strong>: China\u2019s <strong>AI\u2011enabled drug discovery market<\/strong> is projected to reach <strong>\u00a515\u202fbillion<\/strong> by 2028, growing at a <strong>35% CAGR<\/strong>, driven by demand for faster, more cost\u2011effective R&amp;D.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding the Insilico\u2011Hisun partnership\u2019s development timeline, AI platform capabilities, and market potential. Actual results may differ due to clinical outcomes, competitive dynamics, and regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52709,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,766,4514,164,1466],"class_list":["post-52707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-hisun-pharmaceutical","tag-hkg-3696","tag-insilico-medicine","tag-sha-600267"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s Pharma.AI platform in accelerating early\u2011stage drug discovery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52707\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s Pharma.AI platform in accelerating early\u2011stage drug discovery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52707\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-04T07:02:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-04T07:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform\",\"datePublished\":\"2026-01-04T07:02:05+00:00\",\"dateModified\":\"2026-01-04T07:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707\"},\"wordCount\":290,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0405.webp\",\"keywords\":[\"AI\",\"Hisun Pharmaceutical\",\"HKG: 3696\",\"Insilico Medicine\",\"SHA: 600267\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52707#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52707\",\"name\":\"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0405.webp\",\"datePublished\":\"2026-01-04T07:02:05+00:00\",\"dateModified\":\"2026-01-04T07:02:06+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s Pharma.AI platform in accelerating early\u2011stage drug discovery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52707\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52707#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s Pharma.AI platform in accelerating early\u2011stage drug discovery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52707","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform","og_description":"Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s Pharma.AI platform in accelerating early\u2011stage drug discovery.","og_url":"https:\/\/flcube.com\/?p=52707","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-04T07:02:05+00:00","article_modified_time":"2026-01-04T07:02:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52707#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52707"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform","datePublished":"2026-01-04T07:02:05+00:00","dateModified":"2026-01-04T07:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52707"},"wordCount":290,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52707#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp","keywords":["AI","Hisun Pharmaceutical","HKG: 3696","Insilico Medicine","SHA: 600267"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52707#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52707","url":"https:\/\/flcube.com\/?p=52707","name":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52707#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52707#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp","datePublished":"2026-01-04T07:02:05+00:00","dateModified":"2026-01-04T07:02:06+00:00","description":"Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico\u2019s Pharma.AI platform in accelerating early\u2011stage drug discovery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52707#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52707"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52707#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp","width":1080,"height":608,"caption":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52707#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52707"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52707\/revisions"}],"predecessor-version":[{"id":52710,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52707\/revisions\/52710"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52709"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}